Dynavax Technologies Corporation
DVAXDynavax Technologies Corporation (DVAX) is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases, oncology, and autoimmune conditions. The company is known for its COVID-19 vaccine, leveraging its expertise in immunology and vaccine technology to address various public health challenges.
Company News
Dynavax reported strong Q3 2025 financial results, with HEPLISAV-B vaccine revenue increasing 13% to $90 million. The company entered an exclusive license agreement with Vaxart for an oral COVID-19 vaccine and authorized a new $100 million share repurchase program.
Dynavax Technologies exceeded Q2 2025 analyst expectations with $95.4 million in revenue and $0.14 EPS, driven by record sales of HEPLISAV-B hepatitis B vaccine and strong market share growth.
The global vaccine adjuvants market is projected to grow from USD 3.83 billion in 2024 to USD 5.43 billion by 2032, with a 4.47% CAGR, driven by increasing vaccine efficacy demands and global immunization programs.
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -40% and 2.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
